Fabrizio Di Giuseppe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Fabrizio Di Giuseppe has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Carmine Di Ilio
Department of Biomedical Science, G d'Annunzio University, Chieti-Pescara, Italy
1 shared publication - Enrica Eleuterio
Department of Biomedical Science, G d'Annunzio University, Chieti-Pescara, Italy
1 shared publication - Giuseppe Sabatino
Neonatal Intensive Care Unit, University of Chieti, Italy
1 shared publication - Laura Pierdomenico
Department of Medicine and Aging Science, School of Medicine and Health Sciences, University "G. d'Annunzio" Chieti-Pescara, via dei Vestini 31, 66013, Chieti, Italy
1 shared publication - Marco Marchisio
Department of Medicine and Aging Sciences, University “G. d’Annunzio” of Chieti-Pescara, 66100 Chieti, Italy
1 shared publication - Marilisa Sulpizio
Department of Biomedical Science, G d'Annunzio University, Chieti-Pescara, Italy
1 shared publication
Latest Publications
- Open Access
- 1 January 2010
- Published by Springer Nature in Proteome Science
- Vol. 8 (1) , 18
Proteome analysis of human Wharton's jelly cells during in vitro expansion
The human umbilical cord contains mucoid connective tissue and fibroblast-like cells. These cells named Wharton's jelly cells, (WJCs) display properties similar to mesenchymal stem cells therefore representing a rich source of primitive cells to be potentially used in regenerative medicine. To better understand their self-renewal and potential in vitro expansion capacity, a reference 2D map was constructed as a proteomic data set. 158 unique proteins were identified. More than 30% of these proteins belong to cytoskeleton compartment. We also found that several proteins including Shootin1, Adenylate kinase 5 isoenzyme and Plasminogen activator-inhibitor 2 are no longer expressed after the 2nd passage of in vitro replication. This indicates that the proliferative potency of these cells is reduced after the initial stage of in vitro growing. At the end of cellular culturing, new synthesized proteins, including, ERO1-like protein alpha, Aspartyl-tRNA synthetase and Prolyl-4-hydroxylase were identified. It is suggested that these new synthesized proteins are involved in the impairment of cellular surviving during replication and differentiation time. Our work represents an essential step towards gaining knowledge of the molecular properties of WJCs so as to better understand their possible use in the field of cell therapy and regenerative medicine.
- 1 January 2010
- Published by Springer Nature in Proteome Science
- Vol. 8 (1) , 18
Open AccessProteome analysis of human Wharton's jelly cells during in vitro expansion
The human umbilical cord contains mucoid connective tissue and fibroblast-like cells. These cells named Wharton's jelly cells, (WJCs) display properties similar to mesenchymal stem cells therefore representing a rich source of primitive cells to be potentially used in regenerative medicine. To better understand their self-renewal and potential in vitro expansion capacity, a reference 2D map was constructed as a proteomic data set. 158 unique proteins were identified. More than 30% of these proteins belong to cytoskeleton compartment. We also found that several proteins including Shootin1, Adenylate kinase 5 isoenzyme and Plasminogen activator-inhibitor 2 are no longer expressed after the 2nd passage of in vitro replication. This indicates that the proliferative potency of these cells is reduced after the initial stage of in vitro growing. At the end of cellular culturing, new synthesized proteins, including, ERO1-like protein alpha, Aspartyl-tRNA synthetase and Prolyl-4-hydroxylase were identified. It is suggested that these new synthesized proteins are involved in the impairment of cellular surviving during replication and differentiation time. Our work represents an essential step towards gaining knowledge of the molecular properties of WJCs so as to better understand their possible use in the field of cell therapy and regenerative medicine.